Bio-Gene Technology Limited

A$0.01As of Sun 8 Nov 2026, 12:00 UTC
ASX:BGTHealthcare
Country Australia
PE (Fwd) •••
TSR 9Y CAGR (27.13%)
Div yield —
ROE (125.40%)
Biotechnology
Beta (5Y) 0.79
PE TTM —
TSR TTM (48.00%)
Mkt cap A$5.695M
ROIC (79.21%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$0.0148
14.06%
(52.56%)
Hold 6|1|6|7|10
2Q26
3Q26
4Q26
1Q27
Earnings per share$
—
—
—
—
13.34%
6.44%
6.62%
17.23%
Revenue$M
0.593
0.596
0.586
0.621
(6.06%)
(3.26%)
(2.70%)
2.75%
Peers (US$3.911M)
Cap (US$)
PE
3.826M
—
3.645M
—
3.889M
13.77x
Capital
TTM
5Y
10Y
Leveragex
0.903
(0.249)
(0.193)
EBIT/Intx
1.151
0.416
0.405
Own earn%
125.31
148.04
166.25
Sh yield%
52.81
26.22
26.09
Owners
Insiders/Inst%
12.41
63.19
Short interest%
5.98
SBC / revenue%
2.98
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
17
Op margin range%
17–24
$1 testx
0.2
Incr. ROIC%
6